Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930537 | 0.88 | TSHR (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL3415640 | 0.88 | TSHR (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL2932492 | 0.86 | MKNK1 (0.40) | HCRTR1HCRTR2PIK3CAHTT | |
| SCHEMBL2923800 | 0.83 | HCRTR1 (0.48) | HCRTR1HCRTR2CDK4CCND1HTT | |
| SCHEMBL2925286 | 0.82 | HCRTR1 (0.44) | HCRTR1HCRTR2CDK4CCND1KMT2A | |
| SCHEMBL3416998 | 0.82 | HCRTR2 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL2924530 | 0.82 | SLC6A4 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL2931896 | 0.82 | HCRTR2 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL3415826 | 0.82 | HCRTR1 (0.44) | HCRTR1HCRTR2CDK4CCND1KMT2A | |
| SCHEMBL3416131 | 0.81 | CDK4 (0.41) | HCRTR1HCRTR2CDK4CCND1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | claimed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | claimed |
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885CDK4 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.